Reduced incidence of tick paralysis cases in dogs and cats at two emergency clinics in South-East Queensland since 2015: new generation prophylactics as possible explanatory variables.

INTRODUCTION: This study aimed to determine the incidence of canine and feline tick paralysis cases presenting to two veterinary emergency hospitals before and after the introduction of new generation prophylactic acaricides. METHODS: This was a retrospective study, investigating the number of tick paralysis cases presenting to two emergency and critical care veterinary hospitals in South-East Queensland, from 2008 to 2021. A total of 10,914 dogs and 3696 cats were included over the course of the study. To assess if the introduction of new generation prophylactics in 2015 has coincided with any variation in case numbers, data for each species were analysed graphically and numerically in the first instance, then interrupted time series analyses were performed for the dog and cat data independently. RESULTS: Accounting for seasonal and climatic variation, we estimated a 54.8% reduction in dog (95% CI 45.3%-62.7%) and 44% reduction in cat (95% CI 19.5%-46%) tick paralysis cases presenting to these two clinics. This reduction corresponded with the timing of new generation prophylactic agents being introduced, including isoxazolines and imidacloprid/flumethrin impregnated collars. CONCLUSION: In the population studied, a significant reduction in the incidence of tick paralysis cases treated by veterinarians has occurred from 2015 onwards and was found to be associated with the timing of the release of new generation acaricidal products.

A retrospective study of cane toad (Rhinella marina) toxicity in 190 domestic cats in Southeastern Queensland: Clinical presentations, treatments, and outcomes.

OBJECTIVE: To report the clinical presentations, treatments and outcomes of toad toxicity in domestic cats in Southeastern Queensland, Australia. METHODS: This report describes a retrospective study of 190 cases of cane toad (Rhinella marina) toxicity in cats in south-eastern Queensland, Australia. All cases were presented for veterinary treatment between 2011 and 2020 at four specialist veterinary emergency centres in Southeast Queensland, Australia. Cane toad toxicity was diagnosed based on a history of exposure and clinical signs. RESULTS: Domestic short-hair breeds accounted for 53.6% of the cases. Presentation was seasonal with the highest incidence over the warmer months of the year (November - March). Hypersalivation was described in 96.3% (183/190), tachypnoea in 34.2% (65/190) and altered behaviour in 18.4% (35/190) of cases. Seizures occurred in 1% of cases. Of the 190 cases, 6.3% (12/190) were hospitalised and 0.5% (1/190) were euthanised and overall 99.5% (189/190) survived hospital discharge. CLINICAL SIGNIFICANCE: Cane toad toxicity is relatively common in cats in Southeast Queensland and following buccal lavage the prognosis for recovery was excellent.

Safety and efficacy of a purified canine immunoglobulin G formulation for treatment of 76 cats clinically affected by the Australian paralysis tick (Ixodes holocyclus).

Acute adverse reactions in cats administered unrefined canine paralysis tick (Ixodes holocyclus) antiserum are commonly observed by veterinarians and can lead to significant morbidity and potentially fatal. A purified antiserum canine IgG concentrate was chromatographically prepared and aseptically formulated in single doses containing the equivalent of 5 mL of unrefined tick antiserum (TAS). The IgG was used for slow intravenous infusion into clinically affected cats at multiple veterinary clinics on the eastern seaboard of Australia. Overall, 72/76 (95%) of cats survived hospital discharge, an efficacy comparable to published data. A subset of 22 cats previously treated with unrefined TAS and considered high risk were included in the dataset. The safety profile was excellent with 0/76 acute adverse reactions although 2/76 (2.6%) developed mild facial swelling within 2 h of infusion that responded to the antihistamine. In conclusion, cats intravenously infused with purified IgG from canine TAS did not exhibit the expected frequency of acute adverse reactions during infusion and it was both safe and effective for the treatment of tick paralysis in cats.

A review of 91 canine and feline red-bellied black snake (Pseudechis porphyriacus) envenomation cases and lessons for improved management.

INTRODUCTION: Most cases of red-bellied black snake (RBBS) envenomation in dogs respond favourably to treatment comprising of tiger-brown snake antivenom (TBAV), intravenous fluid therapy, analgesia and, if indicated, mechanical ventilation and/or blood transfusion. However, there remains a subset of patients who develop fatal complications despite intensive treatment and risk factors for these occurring remain unknown. Here we present a retrospective cross-sectional survey of 91 canine and feline RBBS envenomation cases. METHODS: Cases seen between June 2010 and June 2020 were retrieved from the databases of seven practices in South East and coastal Queensland. From the canine case population, logistic regression analysis was performed to assess the impact of potential risk factors at presentation on the likelihood of death. A final multivariable model was developed using a manual backwards elimination approach based on overall likelihood ratio tests and Wald chi-square P-values for each variable. Where model convergence failed due to quasi-complete separation, Firth's penalised maximum likelihood method was implemented. Such separation may occur when an outcome is completely predicted by an explanatory variable in one group. RESULTS: Of the 88 canine cases, 7 died (8.0%), all after prognosis-based euthanasia. Of the three feline cases, one died after unsuccessful resuscitation following cardiopulmonary arrest. Compared to survivors, dogs that died were older, exhibited pigmenturia, received antivenom later and had a higher total plasma protein (TPP), activated clotting time (ACT) and lower packed cell volume (PCV) at presentation.

Successful treatment of a potentially fatal eastern brown snake (Pseudonaja textilis) envenomation in a dog with tiger-brown snake antivenom with serial quantification of venom antigen and antivenom concentrations in serum and urine.

CASE REPORT: A successfully treated case of eastern brown snake (Pseudonaja textilis) envenomation in a Jack Russel Terrier dog is described with measurement of venom and antivenom concentration pre- and post-treatment. Early presentation, prompt administration of tiger-brown snake antivenom, hospitalisation and critical care monitoring lead to low morbidity and rapid recovery from a potentially fatal envenomation. Retrospective measurement of urine and serum venom and antivenom provided insight into the potential severity of the case and rapid efficacy of antivenom. CLINICAL SIGNIFICANCE: Potentially fatal brown snakebite cases may initially present with only mild clinical signs despite having high concentrations of venom and potential for fatal outcome. Prompt treatment with antivenom is essential to prevent the development of progressive and fatal coagulopathy and paralysis.

Associations between interpregnancy interval and preterm birth by previous preterm birth status in four high-income countries: a cohort study.

OBJECTIVE: To investigate the effect of interpregnancy interval (IPI) on preterm birth (PTB) according to whether the previous birth was preterm or term. DESIGN: Cohort study. SETTING: USA (California), Australia, Finland, Norway (1980-2017). POPULATION: Women who gave birth to first and second (n = 3 213 855) singleton livebirths. METHODS: Odds ratios (ORs) for PTB according to IPIs were modelled using logistic regression with prognostic score stratification for potential confounders. Within-site ORs were pooled by random effects meta-analysis. OUTCOME MEASURE: PTB (gestational age <37 weeks). RESULTS: Absolute risk of PTB for each IPI was 3-6% after a previous term birth and 17-22% after previous PTB. ORs for PTB differed between previous term and preterm births in all countries (P-for-interaction ≤ 0.001). For women with a previous term birth, pooled ORs were increased for IPI <6 months (OR 1.50, 95% CI 1.43-1.58); 6-11 months (OR 1.10, 95% CI 1.04-1.16); 24-59 months (OR 1.16, 95% CI 1.13-1.18); and ≥ 60 months (OR 1.72, 95%CI 1.60-1.86), compared with 18-23 months. For previous PTB, ORs were increased for <6 months (OR 1.30, 95% CI 1.18-1.42) and ≥60 months (OR 1.29, 95% CI 1.17-1.42), but were less than ORs among women with a previous term birth (P < 0.05). CONCLUSIONS: Associations between IPI and PTB are modified by whether or not the previous pregnancy was preterm. ORs for short and long IPIs were higher among women with a previous term birth than a previous PTB, which for short IPI is consistent with the maternal depletion hypothesis. Given the high risk of recurrence and assuming a causal association between IPI and PTB, IPI remains a potentially modifiable risk factor for women with previous PTB. TWEETABLE ABSTRACT: Short versus long interpregnancy intervals associated with higher ORs for preterm birth (PTB) after a previous PTB.

SnakeMap: four years of experience with a national small animal snake envenomation registry.

SnakeMap is a national cloud-based, veterinary snakebite registry. It was designed to prospectively collect data of the clinical circumstances and temporospatial information on cases of snake envenomation in dogs and cats. We herein introduce the project and summarise the data from the first 4 years of SnakeMap. The registry is a veterinary community-based online database allowing case entry from veterinary hospitals across Australia. Registry data comprise hospital characteristics, patient characteristics, envenoming snake type, treatment and outcome variables, including time and geolocation of the snake bite. We present summative information on select key variables from the SnakeMap registry (1 July 2015 to 30 June 2019). Twenty-eight hospitals from 6 states/territories entered 624 cases into the registry, including 419 dogs (67%) and 205 cats (33%). Bite time was available in 216 animals of which 90 (42%) were reported to be bitten in the 3 hours between 03:00 pm and 05:59 pm; median bite to presentation interval was 60 (interquartile range [IQR] 30, 211) minutes in dogs and 95 (IQR 41, 238) minutes in cats. Bites occurred in the owner's yard in 356 dogs (85%) and 53 cats (26%). A snake venom detection kit was used in 172 cases (28%) and antivenom was administered in 523 cases (85%). Most animals (n = 534, 88%) survived to discharge (median hospitalisation of 25 [IQR 16, 62] hours). SnakeMap effectively collects relevant clinical data from dogs and cats with presumed snake bite and provides locally specific information on the epidemiology of snake envenomation in small animals.

Red-bellied black snake (Pseudechis porphyriacus) envenomation in 17 dogs: clinical signs, coagulation changes, haematological abnormalities, venom antigen levels and outcomes following treatment with a tiger-brown snake antivenom.

BACKGROUND: This report describes 17 cases of red-bellied black snake envenomation (RBBS; Pseudechis porphyriacus) in dogs in south-eastern Queensland. Patients were prospectively enrolled for the treatment with a new tiger-brown snake antivenom 8000 units, (TBAV; Padula Serums Pty Ltd, VIC, Australia). CASE REPORT: Clinical diagnosis of RBBS envenomation was made by either snake venom detection kit, snake identification using scale counting, or owner observed dog-snake interaction in patients with clinical signs of envenomation. An RBBS venom antigen sandwich ELISA was used to retrospectively quantify venom levels in frozen serum and urine. Mechanical ventilation was required in 11% (2/17) patients, whole blood transfusion in 12% (2/17), tissue swelling at the bite site occurred in 53% (9/17) and facial palsy in 12% (2/17). One dog was euthanised, and overall, 94% (16/17) survived to hospital discharge. Clinicopathological changes pre-TBAV included variable haemolysis, increased CK, pigmenturia and mildly prolonged active clotting time with a median of 134 s (n = 13, range 91-206 s). Haematological profiles post envenomation revealed anaemia (6/6) and spherocytosis (5/5), which resolved without the use of corticosteroids. Pre-TBAV, median RBBS venom antigen concentration was 22.6 ng/mL (n = 15, range 2-128) in serum and 58 ng/mL (range 1-452) in urine; RBBS venom antigen was undetectable in serum post-TBAV in all patients. CONCLUSION: Some RBBS envenomed dogs required, critical care including mechanical ventilation, blood transfusion, additional antivenom and prolonged hospitalisation. TBAV was effective with excellent prognosis despite stated specificity for tiger and brown snake.

Tick paralysis in dogs and cats in Australia: treatment and prevention deliverables from 100 years of research.

This review of tick paralysis caused by Ixodes holocyclus in Australia addresses the question: What are the key discoveries that have enabled effective treatment and prevention of tick paralysis in dogs and cats? Critical examination of 100 years of literature reveals that arguably only three achievements have advanced treatment and prevention of tick paralysis in animals. First, the most significant treatment advance was the commercial availability of tick antiserum in the 1930s. Hyperimmune serum currently remains the only specific anti-paralysis tick therapy available to veterinarians in Australia. Second, advances in veterinary critical care have increased survival rates of the most severely affected dogs and cats. Critical care advancements have been enabled through specialised veterinary hospitals that can provide appropriate care 24 h a day, and advanced training of veterinarians, veterinary nurses and technicians. Third, perhaps that biggest advance of all in the last 100 years of research has been the commercial availability of the isooxazoline class of acaricidal preventatives in Australia specifically for I. holocyclus. This highly effective class of preventatives offers long duration of action, low cost, spot-on or oral formulations and a low rate of adverse reactions. Animal owners and veterinarians now have the most useful tool of all - a reliable preventative. This review reveals the key events in research over the last 100 years and the tortuous pathway to delivering better treatment and preventative options for this enigmatic Australian parasite.

Severe haemolysis and spherocytosis in a dog envenomed by a red-bellied black snake (Pseudechis porphyriacus) and successful treatment with a bivalent whole equine IgG antivenom and blood transfusion.

This case report describes a dog envenomed by a red-bellied black snake (RBBS; Pseudechis porphriacus) that experienced severe and life-threatening haemolysis. The dog presented with hypersalivation, facial swelling, mildly prolonged activated clotting time and the absence of neurological deficits. Envenomation was confirmed by positive identification of the snake and retrospective measurement of RBBS specific venom antigen (24 ng/mL) in serum. The dog was initially hospitalised, treated with intravenous fluids and one vial of tiger-brown snake antivenom which is recommended for RBBS envenomation in Australia. However, after 3.5 d the dog's PCV had declined to 15% and the dog was dull and tachycardic. A second vial of tiger-brown antivenom followed by a packed red blood cell transfusion was administered. A rapid clinical improvement within 12 h was observed. No free RBBS venom was detected in serum at any time point after the first vial of antivenom. Longitudinal haematology and biochemical profiling was performed to 62 d post-envenomation and revealed a gradual recovery in the haematocrit to normal reference range. Spherocyte numbers on blood smear were highest at 5 d post-envenomation and gradually declined to undetectable after 62 d. This case highlights the potential for unpredictable, severe and life-threatening anaemia resulting from RBBS envenomation in dogs.

Severe neurotoxicity requiring mechanical ventilation in a dog envenomed by a red-bellied black snake (Pseudechis porphyriacus) and successful treatment with an experimental bivalent whole equine IgG antivenom.

Snakebite in dogs from Pseudechis porphyriacus (red-bellied black snake; RBBS) is a common envenomation treated by veterinarians in Australia where this snake occurs. This case report describes the successful treatment of a clinically severe RBBS envenomation in a dog with an experimental bivalent equine whole IgG antivenom and mechanical ventilation, following its presentation in a cyanotic state. The cause of the cyanosis and respiratory distress was considered due to paralysis from neurotoxins in RBBS venom. The dog was treated with two vials of bivalent antivenom, each containing sufficient antivenom to neutralise the lethal effects of 40 mg of tiger snake (Notechis sp) and 40 mg of brown snake (Pseudonaja sp) venom. Hypoxaemia (Sp02 of 75%) and hypercapnia (PaCO2 of 61 mmHg) indicated the need for mechanical ventilation (MV) to prevent imminent death. The dog was anaesthetised using total intravenous anaesthesia and MV used for 18 h. Following discontinuation of MV, it resumed spontaneous breathing thereafter and made a complete recovery. Serum biochemistry revealed a significant myopathy with elevated CK and AST levels, peaking approximately 48 h post-treatment. Elevated liver enzymes, suggestive of hypoxic liver injury, were detected during the period of hospitalisation. The dog represented approximately one week after hospital discharge because of inappetence and mild hepatopathy, which resolved spontaneously by 30 d post-treatment. A mild coagulopathy was initially present which resolved within 24 h following antivenom treatment. At initial presentation, RBBS venom antigen was detected by sandwich ELISA in urine and serum. Free RBBS venom antigen was not detected post-antivenom treatment. Human cases of RBBS requiring ventilatory support are rare. This unusual case of RBBS envenomation in a dog highlights its potential clinical severity in dogs, and the need for early, aggressive, MV to achieve a successful outcome in cyanosed and clinically severe cases.

Eastern brown snake (Pseudonaja textilis) envenomation in dogs and cats: Clinical signs, coagulation changes, brown snake venom antigen levels and treatment with a novel caprylic acid fractionated bivalent whole IgG equine antivenom.

This report describes the diagnosis and treatment of 16 confirmed cases of snakebite from the Australian eastern brown snake (Pseudonaja textilis) in dogs and cats. The clinical signs, brown snake venom antigen concentrations, coagulation parameters, and treatment outcomes following administration of an experimental caprylic acid fractionated bivalent whole IgG antivenom are documented. A brown snake venom antigen specific sandwich ELISA was used to retrospectively quantify venom levels in serum and urine. The characteristic clinical signs of envenomation in all cases were neurotoxicity to a variable extent and coagulation disturbances. The median serum venom concentration at presentation was 122 ng/mL and ranged from 1.9 to 3607 ng/mL. The median urine venom concentration at presentation was 55 ng/mL and ranged from 3.3 to 2604 ng/mL. Mechanical ventilation was used to successfully support respiration in three severely paralysed cases for 1-30 h. In four cases where serum samples were available post-antivenom treatment, venom was no longer detectable. Coagulation parameters measured on citrated plasma samples collected prior to antivenom from each case were abnormally prolonged to variable degrees in all cases. Three cases (2 dogs; 1 cat) were euthanized within four hours of presentation for either cost based reasons (2) or poor prognosis (1). One dog developed massive and potentially fatal pulmonary haemorrhage and was euthanazed. In vitro testing of the venom procoagulant neutralising efficacy of the experimental antivenom demonstrated it was 9.6-72 times more effective when compared to two other commercial veterinary antivenom products. This is the first detailed report of a case series of P. textilis envenomation in dogs and cats. The envenomation syndrome in dogs and cats differed to that reported humans, dominated by neurotoxicity and coagulopathy; unlike in humans, where coagulopathy is of primary clinical significance.

Effect of treatment with two intravaginal inserts on the uterine and vaginal microflora of early postpartum beef cows.

OBJECTIVE: To describe the bacterial species found within the uterus and vagina of early postpartum (10 to 20 d) beef cows treated for 14 d with (i) two intravaginal (CIDR-B) progesterone releasing inserts (C-P4; n=31); (ii) two identical but blank inserts (C-BL; n=15); (iii) untreated controls (CON; n=15). It was hypothesised that due to the locally immunosuppressive effects of progesterone on the uterus, the bacterial microflora of C-P4 would be altered by this treatment in contrast to CON and C-BL. PROCEDURE: Cows were enrolled at two intervals 7 d apart. Blood samples were collected at 0, 7 and 14 d after beginning treatments for subsequent progesterone assay. A triple guarded swabbing technique was used to collect bacteriological samples from the uterus of every cow on days 0, 7 and 14 following CIDR insertion. Swabs were also collected from the inserts and vagina of every cow on day 14. Due to the small sample sizes, only descriptive statistics were generated. RESULTS: Plasma progesterone levels were maintained at mid-luteal phase concentrations by the intravaginal progesterone releasing inserts (C-P4: 4.2 +/- 0.4 ng/mL at 7 d; 3.6 +/- 0.2 ng/mL at 14 d), although increased progesterone concentrations were found in 4/15 CON and 9/15 C-BL cows on day 14. Bacteria were isolated from 32/61 (52%) of all uterine samples collected at the time of insertion. Uterine and vaginal swabs from CON cows showed a marked reduction in isolates over time such that 14 d after insertion only 1/15 uterine swabs grew bacteria. In contrast, C-BL and C-P4 treated cows failed to show reductions in the number of uterine or vaginal isolates at 14 d after device insertion. Heavy growths of Pseudomonas aeruginosa and Actinomyces pyogenes were found on the intravaginal inserts from C-BL and C-P4 cows. Cows enrolled in the second week of the study that received intravaginal inserts (C-P4 + C-BL) were more likely to have Pseudomonas isolated from the uterus than those enrolled in week 1 (1/18 versus 14/28). CONCLUSIONS: The presence of two intravaginal inserts, regardless of hormone content, substantially altered the profile of uterine and vaginal bacteria in early postpartum beef cows. It was suspected that because of the early stage at insert application, the cervix had not involuted sufficiently to provide an adequate microbial barrier to the uterus. Pseudomonas aeruginosa was the predominant species isolated from both uterine and insert cultures after 14 d of treatment but may have been a contaminant, due to the greater proportion of cows infected with it that had been enrolled in the second week of the study.

Chronic cystic ovarian disease in a Holstein cow.

Cystic ovarian follicles are commonly found during rectal examination of early postpartum dairy cows, usually presenting with anoestrus and occasionally nymphomania. Most cases self cure with time, or respond to exogenous hormonal treatment. This case report describes a refractory case in a Holstein cow in which a novel treatment approach was used. A gonadotrophin releasing hormone agonist implant was inserted for 180 d in an attempt to suppress pituitary gonadotrophin output, arrest abnormal ovarian follicle growth and prevent steroidogenesis. Frequent serial blood samples were collected before and after implant insertion to monitor changes in pulse release of luteinising hormone. Follow up ultrasound scans and blood samples were done to monitor ovarian structures; progesterone and oestradiol were collected at various times over the 180 d period. A normal, cycling herdmate was enrolled as a control. Prior to implant insertion, high frequency and low amplitude luteinising hormone pulses were detected in the cystic cow. Insertion was followed by a sustained surge in the release of luteinising hormone in both cows, but ovulation was not induced in the cystic cow. Plasma oestradiol levels remained consistently elevated and signs of oestrous behaviour were observed. Long term gonadotrophin releasing hormone agonist treatment failed to suppress either ovarian steroid production or cause regression of the cysts by 180 d.

GnRH analogues--agonists and antagonists.

GnRH analogues have achieved widespread clinical use for the control of reproduction in animals. Over 2000 analogues of GnRH have been developed and tested over the last 30 years. Paradoxical anti-fertility effects are seen when the more potent agonists are delivered continuously to animals. The evaluation of agonist potency depends largely on the model used and wide varying potencies are reported for the same agonist. The design of analogues has centered on improving the receptor-binding and subsequent activation for agonists. Antagonists have been produced with strong receptor binding but without activation. Deslorelin is classified as a superagonist, with a potency perhaps 100 times that of GnRH. The interactions between agonist potency, dose and duration of treatment largely determine whether pro- or anti-fertility effects are induced. Due to the peptide nature of the synthetic analogues oral administration and potential gastrointestinal enzymatic degradation poor bioavailability results necessitating a parenteral delivery system. Some GnRH antagonists have been associated with significant histamine release, inhibiting their widespread use. More recently, antagonists have been developed that avoid this side effect without compromising potency. However the GnRH antagonist development has lagged behind that of the agonists, in part related to their high cost of production. In conclusion, GnRH agonists have achieved widespread clinical use in animals for controlling reproduction in either pro- or anti-fertility roles, yet antagonist development has been slower.

Restoration patterns for luteinising hormone and ovarian function following treatment with GnRH agonist implants (deslorelin) for 7, 14 or 21 days in cycling dairy cows.

Continuous GnRH agonist treatment of cows results in downregulation of GnRH responsiveness and a state of induced anoestrus. Inducing anoestrus in a precisely controlled manner could have several potential applications in dairy herd management. However, relatively little is known regarding the processes involved in restoring reproductive normality following an induced anoestrus. This study describes an experiment that was conducted to examine patterns of recovery of LH release and follicle growth in non-lactating Holstein cows immediately following cessation of treatment for 7, 14 or 21 days with a deslorelin implant. Oestrus cycles were synchronized at 7 days intervals and a deslorelin implant inserted in every cow 13 days after detected oestrus so that a group had implants for either 21 days (n = 9), 14 days (n = 10) or 7 days (n = 9). On the day of implant removal every ovarian follicle greater than 4 mm in diameter was ablated using ultrasound guided vacuum needle aspiration in an attempt to standardize follicle sizes. Daily ovarian ultrasound examinations were performed on each cow until 35 days after implant removal and again at 45, 59 and 74 days. A subgroup of four cows randomly selected from each treatment group had frequent serial blood samples collected over 8 h at 4 and 10 days after implant removal for LH profiling. There was no significant effect of treatment duration on any LH parameter and results were pooled. Mean LH pulse amplitude increased by 67% between 4 and 10 days after implant removal (0.34 ng/ml versus 0.57 ng/ml; 4 days versus 10 days post-implant, P < 0.001). Mean pulse frequency remained unchanged between the two samplings (5.9 pulses versus 6.9 pulses per 8 h; 4 days versus 10 days post-implant, P > 0.1). Smoothed mean LH concentrations were unaffected by treatment duration or time (0.36 ng/ml versus 0.41 ng/ml; 4 days versus 10 days post-implant, P > 0.1). The pattern of follicle growth and ovulation did not differ significantly between treatment durations and pooled means were used for comparative descriptions. The emergence of a new follicle wave could be detected beginning at 4 days after implant removal (mean 7.9 +/- 0.8 days). After emergence, a period of rapid follicle growth generally ensued with signs of oestrus occurring when the follicle reached 12.3 +/- 0.5 mm and ovulation when mean follicle diameter was 13.1 +/- 0.7 mm at 13.6 +/- 1.5 days after implant removal. Oestrus preceded ovulation in all cases where ovulation subsequently occurred. The mean interovulatory interval after implant removal was similar amongst groups (18.2 +/- 1.3 days). Follicle growth could be categorized into three groups based on the time to emergence and fate of the first wave DF. Spontaneous recovery was characterised by ovulation of the newly emerged DF. Failure to ovulate the first DF was associated with the formation of a persistent follicle by 35 days after implant removal with some 25% (7/28) of cows showing persistent follicles. Delayed emergence (>14 days after implant removal) was detected in 11% (3/28) of cows, but when a follicle did eventually emerge it was seen to ovulate normally. The correlation between number of days to first oestrus expression and LH pulse amplitude on 4 days post-implant removal was significant (R2 = 44%, P < 0.05). A model was then proposed for the restoration of reproductive function following GnRH agonist removal. In conclusion, duration of deslorelin treatment was associated with only small changes in LH and follicle parameters. The formation of persistent follicles delayed the recovery of more cows than delayed emergence of a new follicle wave after implant removal.

The freemartin syndrome: an update.

The freemartin condition represents the most frequent form of intersexuality found in cattle, and occasionally other species. This review considers the current state of knowledge of freemartin biology, incidence, experimental models, diagnosis, uses for freemartins in cattle herds, occurrence in non-bovine species, effects on the male, and highlights potential new research areas. Freemartins arise when vascular connections form between the placentae of developing heterosexual twin foeti, XX/XY chimerism develops, and ultimately there is masculinisation of the female tubular reproductive tract to varying degrees. With twinning rates in Holstein cows increasing, there will be greater economic importance to establish early diagnosis of the freemartin and the detection of the less common single born freemartin. New diagnostic methods based on the detection of Y-chromosome DNA segments by polymerase chain reaction (PCR) show improved assay sensitivity and efficiency over karyotyping and clinical examination. The implications for the chimeric male animal born co-twin to the freemartin are contentious as to whether fertility is affected; if germ cell chimerism does indeed occur; and, if there are any real effects on the sex ratio of offspring produced. In beef cattle, the freemartin carcass has similar characteristics to normal herdmates. Hormonal treatment of freemartins for use as oestrous detectors has been used to obtain salvage value. The biology of freemartin sheep has recently been studied in detail, and the condition may be increasing in prevalence with the introduction of high fecundity genes into flocks. Potential new research areas are discussed, such as detection of foetal DNA in maternal circulation for prenatal diagnosis and investigation of the anti-tumour properties of Mullerian inhibiting substance (MIS). The freemartin syndrome will always be a limiting factor in cattle and to a lesser extent in sheep production systems that have the goal to produce multiple reproductively normal female offspring from a single dam without using sex predetermination.

Reproductive performance of early postpartum Holstein cows where oestrus was synchronised following chronic GnRH agonist treatment.

OBJECTIVE: The objectives of this study were: to compare the recovery of follicular development in early postpartum cows that had been treated for 7, 14 or 21 d with implants containing the GnRH agonist deslorelin; to evaluate the effectiveness of human chorionic gonadotrophin (hCG) for the induction of ovulation when a follicle was at least 10 mm in diameter following implant removal; and to compare final pregnancy rates for treated cows and untreated contemporaries. PROCEDURE: Within 3 d of calving Holstein cows were allocated to receive a single subcutaneous deslorelin implant to be left in place for either 7, 14 or 21 d, or to remain untreated as controls. Every deslorelin treated cow was monitored twice weekly for 35 d to determine the interval from implant removal to resumption of ovulation using serial transrectal ultrasonography and plasma progesterone assay. An injection of 1000 IU hCG was given to induce ovulation when a follicle of at least 10 mm diameter was first observed. Oestrous cycles of every cow were synchronised to facilitate artificial insemination (Al) at the start of the seasonally concentrated Al program and resynchronised for three rounds. Pregnancy testing was performed by ultrasonography 13 weeks after the first round of Al. RESULTS: Deslorelin implants inhibited ovulation for at least 10 d after they were removed. Ovarian follicles were smaller for the group that had implants for 21 d at the time of implant removal. Eighteen cows selected for treatment with hCG ovulated and formed multiple corpora lutea within 7 d. There was no effect of treatment duration on final pregnancy rates. After three rounds of AI the pooled final pregnancy rate for every cow that had received a deslorelin implant was similar to the rest of the herd (67% versus 63%; Deslorelin versus Herd, P > 0.1). The interval from start date of the AI program to conception was also unaffected by treatment (9.6 +/- 3.0 versus 14.8 +/- 1.7 d; Deslorelin versus Herd; P > 0.1). CONCLUSION: No significant effect was detected on the interval from implant removal to first ovulation by altering the duration of deslorelin treatment. Treatment with hCG when a follicle at least 10 mm in diameter was present induced ovulation in most cases. Although no significant improvement in fertility was found, a larger field trial using this model for induced anoestrous is necessary before any effect on fertility could confidently be stated.

Oestradiol-17beta responsiveness, plasma LH profiles, pituitary LH and FSH concentrations in long-term ovariectomised Holstein cows at 24 h, 48 h and 21 days following treatment with an absorbable GnRH agonist implant.

Non-lactating OVX Holstein cows (N = 34) were used to investigate the effect of s.c. placement of an absorbable GnRH agonist implant (Ovuplant; deslorelin 2.1mg, Peptech Animal Health, Australia) on the relationship of plasma LH, oestradiol responsiveness and pituitary LH content. On the day of implant insertion (Day 0), one group (OVU-48h; N = 5) received Ovuplant and had blood samples collected at hourly intervals to characterize the LH response, while a second group (CON-48 h; N = 5) remained untreated and acted as controls. Blood samples were collected every 10 min over 6 h from CON-48 h and OVU-48 h, at 24 h post-implant insertion. These cows were then slaughtered at 48 h post-implant insertion and their pituitaries recovered. Another group received Ovuplant (OVU-21d+E2; N = 10) or were left untreated (CON-21d+E2) and 21 days later were injected i.m. with 0.5 mg 17beta-E2. Blood samples were collected every 10 min for 4 h on the day before E2 injection to characterize LH pulse frequency and amplitude. Beginning 14 h later, blood samples were collected hourly for 12 h to characterize the expected LH surge. These cows were slaughtered and their pituitary glands recovered and assayed for LH and FSH content. Peak plasma LH concentrations (59 +/- 19 ng/ml) were measured after 30 min of Ovuplant insertion. They had returned to pre-treatment levels by 7 h. By 24 h post-implant insertion, OVU-48 h plasma LH profiles were characterized by reduced LH pulse frequency (0.23 +/- 0.09 pulses/h versus 0.75 +/- 0.26 pulses/h; OVU-48 h versus CON-48 h; P < 0.05). The cows that received Ovuplant had lower LH pulse amplitude, LH pulse frequency and mean LH concentrations after 20 days. Injection of 0.5 mg 17beta-E2 induced an LH surge in every one of the control cows with their peak concentrations measured 18 h post injection. No increase in LH was detected in any Ovuplant treated cows. Pituitary FSH content was reduced in Ovuplant treated cows after 48 h, but not that of LH. In conclusion, absorbable deslorelin implants induced a substantial but temporary release of LH, but even 21 days later their LH profiles were characterized by marked suppression of pulsatile LH and an absence of response to E2. These results suggest the implant has prolonged biological activity.